INGELHEIM, Germany--(BUSINESS WIRE)-- The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate,1 Boehringer Ingelheim’s novel, oral direct thrombin inhibitor2 under the brand name Prazaxa®1 for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.
